Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats

Hwang, Hye Suk; Kim, Ki-Hye; Lee, Youri; Lee, Young-Tae; Ko, Eunju; Park, Soojin; Lee, Jong Seok; Lee, Byung-Cheol; Kwon, Young-Man; Moore, Martin L.; Kang, Sang‐Moo

doi:10.1080/21645515.2016.1272743

Cited by 15 publications

(8 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, F VLP prime only or prime-boost vaccination could prevent pulmonary histopathology lower than that in na€ ıve mice after RSV challenge, which are consistent with the results in cotton rats. 32 Comparative studies of F VLP and F protein vaccination might provide insight into underlying mechanisms by which RSV vaccine-enhanced disease could be avoided, which will to be correlated with mucus production and pathology. 33 CD11b C granulocytes and plasmacytoid DCs infiltrating into the lungs after RSV challenge were suggested to contribute to RSV disease.…”

Section: Discussionmentioning

confidence: 99%

Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles

Lee

et al. 2017

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) fusion (F) protein is suggested to be a protective vaccine target although its efficacy and safety concerns remain not well understood. We investigated immunogenicity, efficacy, and safety of F proteins in a soluble form or on virus-like particle (F-VLP). F VLP preferentially elicited IgG2a antibody and T helper type 1 (Th1) immune responses whereas F protein induced IgG1 isotype and Th2 responses. Despite lung viral clearance after prime or prime-boost and then RSV challenge, F protein immune mice displayed weight loss and lung histopathology and high mucus production and eosinophils. In contrast, prime or prime-boost vaccination of F VLP induced effective protection, prevented infiltration of eosinophils and vaccine- enhanced disease after challenge. This study provides insight into developing an effective and safe RSV vaccine candidate.

show abstract

Section: Discussionmentioning

confidence: 99%

Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles

Lee

et al. 2017

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Another promising vaccine candidate was developed by Hwang et al [ 92 ]. They demonstrated the immunogenicity, efficacy, and safety of virus-like particle vaccines containing RSV F G or F and G proteins in cotton rats.…”

Section: State Of the Art For Active And Passive Prophylaxis Againmentioning

confidence: 99%

Respiratory Syncytial Virus: The Influence of Serotype and Genotype Variability on Clinical Course of Infection

Vandini

Biagi

Lanari

2017

IJMS

108

103

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) belongs to the recently defined Pneumoviridae family, Orthopneumovirus genus. It is the leading cause of acute bronchiolitis and one of the most common causes of infant viral death worldwide, with infection typically occurring as recurrent seasonal epidemics. There are two major RSV subtypes, A and B, and multiple genotypes, which can coexist during RSV epidemic season every year and result in different disease severity. Recently, new RSV genomic sequences and analysis of RSV genotypes have provided important data for understanding RSV pathogenesis. Novel RSV strains do spread rapidly and widely, and a knowledge of viral strain-specific phenotypes may be important in order to include the more virulent strains in future therapeutical options and vaccine development. Here we summarize recent literature exploring genetic and molecular aspects related to RSV infection, their impact on the clinical course of the disease and their potential utility in the development of safe and effective preventive and therapeutic strategies.

show abstract

“…Pre-F/F VLPs immunization protected cotton rats and did not result in enhanced lung inflammation after RSV challenge. Combined F + G VLP with F DNA vaccination of cotton rats was more effective in inducing RSV neutralizing antibody titers than RSV F but both combined FFG VLP and F VLP vaccination prevented the induction of vaccine-induced inflammation in the lungs, in contrast to FI-RSV [117,118].…”

Section: Vaccine Efficacy Of Rsv Vlp Vaccinesmentioning

confidence: 91%

Progress in the development of virus-like particle vaccines against respiratory viruses

Quan

Basak

Chu

et al. 2020

Expert Review of Vaccines

Self Cite

View full text Add to dashboard Cite

Introduction: Influenza virus, human respiratory syncytial virus (RSV), and human metapneumovirus (HMPV) are important human respiratory pathogens. Recombinant virus-like particle (VLP) vaccines are suggested to be potential promising platforms to protect against these respiratory viruses. This review updates important progress in the development of VLP vaccines against respiratory viruses. Areas Covered: This review summarizes progress in developing VLP and nanoparticle-based vaccines against influenza virus, RSV, and HMPV. The PubMed was mainly used to search for important research articles published since 2010 although earlier key articles were also referenced. The research area covered includes VLP and nanoparticle platform vaccines against seasonal, pandemic, and avian influenza viruses as well as RSV and HMPV respiratory viruses. The production methods, immunogenic properties, and vaccine efficacy of respiratory VLP vaccines in preclinical animal models and clinical studies were reviewed in this article. Expert opinion: Previous and current preclinical and clinical studies suggest that recombinant VLP and nanoparticle vaccines are expected to be developed as promising alternative platforms against respiratory viruses in future. Therefore, continued research efforts are warranted. ARTICLE HISTORY

show abstract

Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats

Cited by 15 publications

References 37 publications

Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles

Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles

Respiratory Syncytial Virus: The Influence of Serotype and Genotype Variability on Clinical Course of Infection

Progress in the development of virus-like particle vaccines against respiratory viruses

Contact Info

Product

Resources

About